Skip to main content
. Author manuscript; available in PMC: 2020 Feb 1.
Published in final edited form as: Circ Res. 2019 Feb;124(3):437–450. doi: 10.1161/CIRCRESAHA.118.313129

Figure 6. Interleukin-1β Inhibition and Lung Cancer.

Figure 6.

Cumulative incidence of lung cancer (left) and fatal lung cancer (right) among CANTOS participants randomly allocated to placebo, canakinumab 50mg, canakinumab 150mg, or canakinumab 300mg. Adapted from Ridker et al, Lancet 2017;390:1833–42.